Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.…
Myriad Genetics (MYGN) Stock Gets Fair Value Boost After Prenatal Sale And Q3 Update
Myriad Genetics (NASDAQ: MYGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 2,700 employees.
The shares were at 5.460 USD on 20 November 2026, down 13.3% over 52 weeks. Its 52-week range is 2.740 USD to 8.090 USD: the price is 32.5% below the high and 99.3% above the low.
Its market capitalisation is 523.74M USD.
Myriad Genetics reports return on equity of -99.4%, an operating margin of -13.3% and revenue down 1.5% year over year.
Its debt exceeds its cash by 102.30M USD, a debt-to-equity ratio of 0.57. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Hold; their mean price target of 5.900 USD is 8.1% above the current price. The next earnings report is expected on 23 February 2027.